305P - Real-world health-related quality of life (HRQoL) among HER2-negative (HER2-) advanced breast cancer (ABC) patients in EU3 and US

Background

Survival outcomes of treatments for ABC are documented in real world settings, however, less is known about HRQoL. This study examined patient HRQoL by treatment line in HER2- ABC patients in the US and EU3 (France, Italy, Spain).

Methods

Oncologists in the US and EU3 were recruited to abstract data from medical records for their next 8-12 consulting HER2- ABC patients in 2019/2020. Patients were invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ C30 and QLQ BR23 questionnaires. Meaningful differences between region in EORTC QLQ C30 scores (Cocks, 2010) and EORTC QLQ BR23 scores (Osoba, 1998) were reported.

Results

The analysis included 597 HER2- ABC patients (US=101; EU3=496) aged 62 years on average. At time of data collection, 49% of patients were on 1^st line (1L) treatment, 41% on 2^nd line (2L) and 10% on 3^rd line or later (3L+). Combination hormone plus targeted therapy were the most common 1L (overall: 61%; US: 67%; EU3: 59%) and 2L (overall: 40%; US: 50%; EU3: 37%) treatments. EU3 1L patients had worse dyspnoea, insomnia, constipation, diarrhoea, systemic therapy side effects, breast symptoms, upset by hair loss, future perspective, and body image but less financial difficulties than US patients. EU3 2L patients reported worse emotional functioning, social functioning, fatigue, nausea/vomiting, pain, dyspnoea, constipation, diarrhoea, systemic therapy side effects, upset by hair loss, future perspective, body image, sexual functioning and sexual enjoyment but less financial difficulties than US patients. Chemotherapy was the most common 3L+ treatment (49% overall) and with only 59 patients with HRQoL outcomes, therefore no comparisons across regions were made for 3L+. EORTC mean global health status scores were 65.1 in 1L (US: 66.7; EU3: 64.7), 60.4 (US: 62.0; EU3: 60.1) in 2L and 57.9 in 3L+ patients, respectively.

Conclusions

Decreased HRQoL was seen from 1L to 3L+; EU3 patients typically reported lower HRQoL than US patients, which may reflect differences in clinical characteristics, treatment patterns, response to treatment, adverse event management, social security, and anthropologic factors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Eisai Inc.

Disclosure

K. Lewis, E. Clayton, A. Lambert: Financial Interests, Institutional, Full or part-time Employment: Adelphi Real World. K. Ndirangu, Q. Zhao, G. Meier: Financial Interests, Institutional, Full or part-time Employment: Eisai. I. Chabot: Financial Interests, Personal, Full or part-time Employment, Contractual consultant: Eisai.